Published4. November 2024, 16:02
Quarterly figures: Biontech can increase sales through adapted corona vaccine
Biontech brought an adapted Covid-19 vaccine onto the market earlier than last year – this is also reflected in the quarterly figures.
The pharmaceutical company Biontech can record profits again.
Boris Roessler/dpa
Comparatively early approvals for adapted corona vaccines drove up the sales of the Mainz-based company Biontech in the third quarter. Overall, the proceeds amounted to 1.24 billion euros, as Biontech announced. The bottom line was a profit of 198.1 million euros. In the previous quarter, the Mainz company had to accept a loss of almost 808 million euros.
The variant-adapted Covid-19 vaccines were brought onto the market earlier than in the previous year due to official approvals in the EU, Great Britain and the USA, said CFO Jens Holstein. This contributed to the strong sales in the third quarter (until the end of September). In the third quarter of the previous year, sales were lower at around 895 million euros, while profits at the time were 160.6 million.
Further adjustments are planned for the combination vaccine
Despite sales of around 1.56 billion euros, there was a loss of almost 925 million for the first nine months of the current financial year. For the year as a whole, Biontech now expects sales to be at the lower end of the forecast range between 2.5 billion and 3.1 billion euros.
Together with the US company Pfizer, Biontech is also working on the development of a combination vaccine against flu and Covid-19. After a study in late phase 3, adjustments to the vaccine candidate are currently being examined, and further steps will then be discussed with the health authorities, Biontech said.
Company boss Ugur Sahin also sees progress in the development of cancer drugs. In the case of developments for the treatment of lung and breast cancer, for example, studies are underway that will later help in the planning of the phase 3 studies relevant for approval. Biontech is aiming for the first market approval for a cancer drug in 2026, and from then on annual market approvals in oncology are planned.
Are you already following us on WhatsApp?
Subscribe to our channel, activate the little 🔔 and get one News overview as well as exciting stories and entertainment at the end of the day.
(DPA)
